Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion

Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion

Abstract Background Faricimab, the new anti-vascular endothelial growth factor (VEGF) drug including a bispecific antibody targeting both VEGF-A and angiopoietin-2 (Ang-2), has emerged as a therapeutic option for macular edema secondary to retinal vein occlusion (RVO), and its efficacy has been demo...

Full description

Saved in:
Bibliographic Details
Main Authors: Toshiaki Hirakata, Ai Toride, Kenta Ashikaga, Takanori Nakagawa, Fumihiro Hara, Yuta Nochi, Shutaro Yamamoto, Yoshimune Hiratsuka, Shintaro Nakao
Format: Article
Language:English
Published: BMC 2025-07-01
Series:International Journal of Retina and Vitreous
Subjects:
PRN
Retinal vein occlusion
Faricimab
Macular edema
Vascular endothelial growth factor
Online Access:https://doi.org/10.1186/s40942-025-00703-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40942-025-00703-3

Similar Items